|

Zilongjin tablet combined with immunotherapy Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2/3: 1

Top Sponsors

  • Kong Fanming1

Indications

  • Immune Checkpoint Inhibitors1
  • Electroacupuncture1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Other1 trial

Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.